INNATE PHARMA (EPA:IPH) “Immunology and Innate Immunity are Keys to Cancer Treatment” Conclusions of the Roundtable of internationally renowned speakers, including winners of the 2011 Nobel Prize in Medicine

Transparency directive : regulatory news

21/05/2012 07:15

"Immunology and Innate Immunity are Keys to Cancer Treatment"
Conclusions of the Roundtable of internationally renowned speakers, including
winners of the 2011 Nobel Prize in Medicine

Immunotherapy and innate immunity targets are at the heart of the search for
long-term, high quality of life responses for patients

Paris and Marseille, May 21, 2012: Bristol-Myers Squibb France and Innate Pharma
are pleased to announce that the roundtable "Innate immunity: from revolutionary
discovery to revolution in therapy", held on 15 May in Paris was a great
success, with the participation of more than 150 international guests from
across medical and scientific fields. The panel of internationally renowned
speakers included special guests Bruce Beutler and Jules Hoffman, winners of the
2011 Nobel Prize in Medicine. The event highlighted the recent successes of
immunotherapies and the significant therapeutic potential of targeting innate
immunity.

Prof. Philippe Kourilsky, Chair of Immunology at the College de France, who
chaired the event said: "Immunology is now a major source of new anti-cancer
products: after years of targeting the tumor itself with undeniable success,
targeting the immune system could achieve high quality long term responses in
cancer patients. Stratification is now one of the major challenges of
immunotherapy: we have tools but we need usable immunological biomarkers to
perform stratification of patients and tumors. Combinations with tumor-targeting
therapies, as well as combinations of different immunotherapies will be also
necessary. In this context, there is no doubt that innate immunity manipulation
will permit the emergence of groundbreaking therapeutic strategies."

Mike Seeley, President of Bristol-Myers Squibb France, said: "It is a very
exciting time. As a number of speakers said today, in five to ten years, we will
be looking at cancer in a completely different way. I am very proud that Innate
Pharma and Bristol-Myers Squibb could be part of a breakthrough in the treatment
of cancer, as controlling simultaneously checkpoints on innate and adaptive
immunity could be keys to prevent immune escape."

Hervé Brailly, CEO of Innate Pharma, said: "We thank the panelists for the
excellent debate which reflected the importance of close collaboration between
researchers, clinicians and industry which is at the heart of Innate Pharma's
business model. Clearly, we have reached an inflexion point: after 30 years of
hope, we now see the major clinical benefits brought by immunotherapy and know
how to address the numerous targets discovered by academic research with
antibodies."

                   Webcast, interviews, summary and more on
                            www.immunite-innee.com

About the roundtable

The round table "Innate immunity: from revolutionary discovery to revolution in
therapy", took place on 15 May in Paris, and included:

- Two 2011 Nobel prize winners in Medicine, Dr. Jules Hoffmann from the
  Institute of Molecular and Cellular Biology at the University of Strasbourg,
  and Dr. Bruce Beutler of the Center for the Genetics of Host Defense at the
  University of Texas, whose scientific discoveries have contributed to the
  elucidation of mechanisms of activation of the innate immune system;
- Professor Jean-Yves Blay, Professor of Medical Oncology, Centre Leon Berard in
  Lyon, chairing the European organization for the research of cancer treatments
(EORTC), who has developed a wealth of experience in cancer immunotherapy;
- Dr. Nils Lonberg, Senior Vice President in charge of research and development
  of biological drugs, Bristol-Myers Squibb, who participated in the development
  of the first antibody modulator of T cells;
- Professor Eric Vivier, Director, Center for Immunology Marseille-Luminy, who
  is a co-founder of Innate Pharma and a specialist of Natural Killer cells.
- Philippe Kourilsky, Chair of Immunology at the College de France and former
  Director ofthe Pasteur Institute, moderated the discussion.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose goal is to
discover, develop and deliver innovative drugs that help patients prevail over
serious diseases. For more information, please visit  www.bmsfrance.fr or follow
us on Twitter at http://twitter.com/#!/bmsnews.

About Innate Pharma

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases. The Company
specializes in the development of new monoclonal antibodies targeting receptors
and pathways controlling the activation of innate immunity cells. The mechanisms
controlling these cells were described at the end of the 90s, notably by the
teams of the scientists who founded Innate Pharma. This innovative approach has
been validated by two major biopharmaceutical partners: Bristol-Myers Squibb in
cancer and Novo Nordisk A/S in inflammation. Learn more about Innate Pharma at
www.innate-pharma.com.

Bristol-Myers Squibb Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined
in the Private Securities Litigation Reform Act of 1995, regarding the research,
development and commercialization of pharmaceutical products. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, includingfactors that could delay, divert or
change any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can be
guaranteed. Forward-looking statements in the press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb's
business, particularly those identified in the cautionaryfactors discussion in
Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December
31, 2010, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Bristol-Myers Squibb undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events, or otherwise.

Innate Pharma Forward-Looking Statements

This press release contains certain forward-looking statements. Although Innate
Pharma (the company) believes its expectations are based on reasonable
assumptions, these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from those
anticipated. For a discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or achievements to
differ from those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website. This press release
and the information contained herein do not constitute an offer to sell or a
solicitation of an offer to buy or subscribe to shares in Innate Pharma in any
country.

Contacts

ATCG Press                        Innate Pharma
Marielle Bricman                  Laure-Hélène Mercier
Director                          Director, Investor Relations

Mob.: +33 (0)6 26 94 18 53        Phone: +33 (0)4 30 30 30 87
mb@atcg-partners.com              Laure-Helene.Mercier@innate-pharma.fr

Bristol-Myers Squibb France
Catherine Liabeuf
Associated Director Public Affairs
Phone: +33 (0)1 58 83 87 92
catherine.liabeuf@bms.com

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) “Immunology and Innate Immunity are Keys to Cancer Treatment” Conclusions of the Roundtable of internationally renowned speakers, including winners of the 2011 Nobel Prize in Medicine

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories